week 8 part 2 Flashcards
(116 cards)
Why do most compounds not become medicines?
- complex disease targets
- Too long in the body
- Adverse reactions
- Poor Absorption
- Low levels in the body
- Not effective enough
- Not sufficiently selective
- Side effects
- Unsafe
- Unstable
- Competition
- Impractical to make
What is pharmacogenomics?
The application of genomic technologies such as gene sequencing, statistical genetics, gene expression analysis to drugs in the clinical development and on the market
What does pharmacogenomics apply to?
large-scale systematic approaches of genomics to speed the discovery of drug response markers, whether they act at the level of the drug target, drug metabolism, or disease pathways.
What is the potential implication of pharmacogenomics in clinical research/medicine?
disease could be treated according to genetic and specific individual markers, selecting medications and dosages that are optimized for individual patients
What is the possibility of defining patient population genetically?
improve outcomes by predicting individual responses to drugs, and could improve safety and efficacy in therapeutic areas such as neuropsychiatry, cardiovascular medicine, endocrinology (diabetes and obesity) and oncology
Where does genetics and genomic fits in?
Its Important in target validation, you can use omics and genetics to identify and validate targets
in lead candidate stage where you are testing for molecule in animal model. what should you look for?
at evolutionary fidelity of animal model
does target in animal model predict action of that target in humans or have evolutionary events caused the function of that target to divergence in animals
What happens in phase I in humans?
- use expression data
- Pathway knowledge
- Anticipate common adverse events that is related to safety
What happens in phase II in humans?
- look at efficacy of drugs
2. Look at common variants
What is pharmacovigilance?
the practice of monitoring the effects of medical drugs after they have been licensed for use, especially in order to identify and evaluate previously unreported adverse reaction
Target ID and validation?
Identification of drug targets based on biological rationale and known small molecule tractibility
Hit and Lead ID
Configure and run high throughput screen to ID bioactive small molecules
identify drug-like lead molecules
Lead to Candidate
Medicinal chemistry to optimise lead properties
Back up lead
Evaluate drug pharmacology in preclinical model
Phase I
Evaluate clinical pharmacology of candidate drug in 20-100 healthy human volunteers
Phase II
Determine therapetuic dose
Evaluate drug efficacy to achieve POC
conducted in 100-200 patients
Phase III & Market
Large comparative study (compound vs placebo) in 1000s of patients to establish clinical benefit and safety
Drug launch and subsequent safety surveillenace
What is Target Validation?
Target validation is the process by which the predicted molecular target – for example protein or nucleic acid – of a small molecule is verified
ongoing process
What does Target Validation include?
- Determining structure-activity-relationship of small molecules
- Generating a drug-resistant mutant of presumed target
- knockdown or overexpression of presumed target
- Monitoring the known signalling systems downstream of presumed target
When can you say a target is validated?
when a drug has been working in the clinic safety and effectively for many years
What is a great example of target validation?
Cox-2
What is Cox-2?
Pain target
target of cox2 inhibitors
What is a dual inhibitor?
Aspirin
Work on Cox-1 and Cox-2
What showed great efficacy in pain?
Selective Cox-2 inhibitors
What is integral to target validation?
Population safety